AMGEN INC AMGN 65.95
Health Care · NASDAQ · Data as of 2026-08-05
AMGEN INC (AMGN) has delivered +5.0% annualized revenue growth, +2.0% earnings growth, and +5.8% dividend growth over 10 years of data. Ranked #368 of 1968 stocks overall and #34 of 260 in the Health Care sector by Steady Score.
About AMGEN INC
Company Overview
Amgen develops and sells biotechnology medicines for serious diseases. Its products treat cancer, cardiovascular disease, osteoporosis, inflammatory conditions and other illnesses, using antibodies, proteins and small molecules. Physicians, hospitals and pharmacies deliver these therapies to patients, with access determined by clinical evidence, regulatory approvals and reimbursement from private and government payers worldwide.
Read more
Business Model & Revenue
Revenue comes from patented medicines sold through healthcare distributors and providers. Prescription volume, approved indications, price, rebates and payer coverage drive sales. Patent expiration brings biosimilar or generic competition, so Amgen invests in discovery, clinical trials, licensing and acquisitions. The Horizon acquisition added rare-disease products, while manufacturing biologic medicines requires specialized facilities and quality control.
Key Facts & Market Position
Amgen combines established biologics with newer oncology, inflammatory and rare-disease franchises. It also develops biosimilars, participating on both sides of biologic patent competition. Product concentration, clinical trial outcomes and government pricing policy can materially alter growth, while reliable global manufacturing is essential for complex therapies.